Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia

  • Technology appraisal guidance
  • TA426
  • Published: 
Download guidance (PDF)

1 Recommendations

1.1 Imatinib is recommended as an option for untreated, chronic-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults.

1.2 Dasatinib and nilotinib are recommended, within their marketing authorisations, as options for untreated chronic-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults. The drugs are recommended only if the companies provide them with the discounts agreed in the relevant patient access schemes.